ESMO Events 2025
ESMO Asia Congress 2025
ESMO Asia is a key gathering for oncology professionals across the Asia-Pacific region, bringing together top experts, researchers, and healthcare providers to advance cancer care and research.
Join us for an exceptional opportunity to explore cutting-edge science, groundbreaking therapies, and innovative practices shaping the future of oncology.
Taking place in Singapore, this annual event features a diverse and dynamic programme, including plenary sessions, multidisciplinary tumour boards, “Meet the Expert” sessions, poster presentations, and networking opportunities. Gain insights into the latest clinical advancements and engage in meaningful discussions with leading minds in oncology.
The ESMO Asia Congress 2025 welcomes participants from all disciplines and levels of expertise, fostering collaboration and the exchange of knowledge.
Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.
Annals of Oncology
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ A. Zer, M.-J. Ahn, F. Barlesi, L. Bubendorf, D. De Ruysscher, P. Garrido, O. Gautschi, L.E. Hendriks, P.A. Jänne, K.M. Kerr, C. Mascaux, T. Mitsudomi, S. Peters, C. Rolfo, A. Sacher, S. Senan, P. Ugalde, N.B. Leighl, on behalf of the ESMO Guidelines Committee
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ T.A. Eyre, K. Cwynarski, F. d’Amore, L. de Leval, M. Dreyling, D.A. Eichenauer, A.J.M. Ferreri, E. Giné, M.J. Kersten, M. Ladetto, L. Specht, C. Thieblemont, J. Walewski, E. Zucca, M. Jerkeman, on behalf of the ESMO Guidelines Committee
ESMO Open
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival☆ J. Crown, D. Stroyakovskii, D.A. Yardley, C.-S. Huang, P.A. Fasching, A. Bardia, Chia, S.-A. Im, M. Martin, B. Xu, C.H. Barrios, M. Untch, R. Moroose, S.A. Hurvitz, G.N. Hortobagyi, D.J. Slamon, F. Visco, G. Spera, J.P. Zarate, D. Halligan, Z. Li, S. Loi
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer D. Tai, T. Conroy, J.J.X. Lee, C.E. Chee, C.-Y. Hao, I. Wijaya, S. Aggarwal, M. Ueno, H.-C. Jeung, N.M. Hashim, J. Tan Chun Bing, L.-T. Chen, K. Korphaisarn, S. Tanasanvimon, W.-C. Chou, E. Cargullo, N.F.A. Muin, M.A. Lee, A. Ohba, S. Bondarde, C.R.A. Lesmana, L. Wang, E.C. Smyth, T. Yoshino, G. Bonney, G. Pentheroudakis, J. Samol, A. Cervantes, E. Poon, M. Ducreux
Immuno-Oncology and Technology
Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives U. Salazar, P. Cioffi, B. Taskoparan, I. Moraga, S. Mitra, J. vom Berg
Harnessing TCR repertoires: predictive insights and therapeutic monitoring in cancer immunotherapy J. Chiffelle, R. Genolet, O. Michielin, A. Harari
ESMO Gastrointestinal Oncology
Development of a novel routine blood-based AI model for HCC screening—a territory-wide study K.-N. Kwok, K.-M. Chueng, S.J.-L. Lam, M. Seo, C.Y. Lau, P.Y.-M. Woo, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, W.W.Y. Sung, H.H.-W. Liu, K.K.-H. Bao, J.C.-H. Chow, S.K.-K. Ng, H.H.-Y. Yiu, D.C.C. Lam
Hypoalbuminemia during zolbetuximab plus chemotherapy for claudin 18.2-positive advanced gastric cancer: a need for caution? K. Shimozaki, A. Ooki, S. Fukuoka, T. Hirasawa, M. Takamatsu, H. Kawachi, T. Wakatsuki, K. Yoshikawa, K. Yoshino, S. Udagawa, H. Osumi, M. Ogura, E. Shinozaki, K. Chin, K. Yamaguchi
ESMO Rare Cancers
A multi-omics analysis of transformed nodal marginal zone lymphoma J.A.A. Bult, Y. Zhong, F.A. de Groot, R.A.L. Groen, N. Veltmaat, D. Al-Sarayfi, A. Seitz, M. Mastik, E. Hilbrands, W.J. Plattel, J. Kluiver, A. van den Berg, S. Rosati, A. Diepstra, J.S.P. Vermaat, M. Nijland
SCOPES: short course of preoperative radiotherapy in head and neck, trunk and extremity soft tissue sarcomas—a randomized phase II clinical trial G.F. Foppele, M. Fiocco, O. Husson, A. Kramer, V.P. Retèl, V. van den Noort, L.M. Wiltink, R.L.M. Haas
ESMO Real World Data and Digital Oncology
Barriers to career development and gender-related challenges in oncology: the results of the JSMO and JSCO surveys in Japan M. Ono, I. Takahashi, T. Kudo, N. Miyazaki, T. Azuma, H. Horinouchi, I. Kinoshita, T.E. Nakajima, T. Yoshino, H. Minami
Outcomes in relapsed/refractory diffuse large B-cell lymphoma in an Asian tertiary cancer center: real-world interventions as benchmark for novel therapy N.-A. Lim, Y. Sun, J.Y. Tan, R.M.H. Lim, Y.H. Tan, L.C.K. Ng, F.L.W.I. Lim, Y.T. Goh, J.T.M. Hoe, J. Chiang, E.W.Y. Chang, E.Y.L. Poon, N. Somasundaram, M. Tao, S.T. Lim, E.S. Mulvihill, A. Hanna-Elias, J.Y. Chan
ESMO affiliated journals
Cost-effectiveness of sacituzumab tirumotecan versus chemotherapy for patients with metastatic triple-negative breast cancer in China Yamin Shu, Ying Tang, Yiling Ding, Pingping Xu, Qilin Zhang
Cost-effectiveness of genetic risk-stratified screening for breast cancer in Taiwan Yu-Chen Hou, Fang-Ju Lin, Yu-Hsuan Joni Shao
Evolving treatment strategies for resectable gastric cancer: Bridging Asia-West disparities toward personalized and integrated therapy Xuesong Zhao, Qianyun Hao, Maria Alsina, Daniel Acosta, Florian Castet, Eduardo Terán, Kreina Vega Cano, Tamara Saurí, Ismael Macías, Takaki Yoshikawa, Sandra Castro, Hirokazu Shoji, Florian Lordick, Zhanlong Shen, Tian V. Tian, Teresa Macarulla
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma Liqiong Xue, Tingting Xu, Guochun Cao, Xiaozhong Chen, Meiyu Fang, Mei Feng, Lin Gui, Fei Han, Yaqian Han, Chuncheng Hao, Man Hu, Wenxiao Huang, Dongmei Ji, Hao Jiang, Shaojun Lin, Lei Liu, Zhigang Liu, Haijun Lu, Song Qu, Guoxin Ren, Ming Song, Peiguo Wang, Xiaoshen Wang, Kunyu Yang, Aimin Yu, Jie Zhang, Shichuan Zhang, Xinxin Zhang, Ye Zhang, Ye Guo, Chaosu Hu
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study Daiki Murata, Koichi Azuma, Kenta Murotani, Kazuhiro Ito, Takashi Nomizo, Kazuhiko Yamada, Tatsuya Imabayashi, Kentaro Iwanaga, Kenji Chibana, Takayo Ota, Yuuya Nishii, Akira Nakao, Asuka Okada, Kosuke Hamai, Keiko Tanimura, Kohei Yoshimine, Yosuke Tamura, Ryuichiro Takaki, Yasuhiro Goto, Makoto Hibino, Tomohiro Oba, Toshiyuki Sumi, Hiroyasu Kaneda, Naoya Nishioka, Tadaaki Yamada, Koichi Takayama
Association of lung silica deposition with epidermal growth factor receptor-mutant lung cancer Shohei Hamada, Yusuke Tomita, Kosuke Fujino, Azusa Miyashita, Jun Morinaga, Remi Mito, Kimitaka Akaike, Hiroko Okabayashi, Aiko Masunaga, Hidenori Ichiyasu, Makoto Suzuki, Takuro Sakagami
Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study Yu-Sung Chang, Chieh-Yu Liu, Yu-Wen Chen, Sheng-Hsuan Huang, Hsing-Yu Lin, Chien-Chin Lin, Xavier Cheng-Hong Tsai, Feng-Ming Tien, Chieh-Lung Cheng, Chang-Tsu Yuan, Yuan-Yeh Kuo, Bor‐Sheng Ko, Ming Yao, Hwei-Fang Tien, Wen-Chien Chou, Hsin-An Hou
Dismal Outcome of EBV-positive Nodal T/NK-cell Lymphoma: A Multicenter Retrospective Study Satoshi Ichikawa, Noriko Fukuhara, Yuna Katsuoka, Yuki Ishizawa, Kosuke Kamata, Masahiko Fukatsu, Takayo Nagao, Kazunori Murai, Hisayuki Yokoyama, Yoshiko Tamai, Takayuki Ikezoe, Ryo Ichinohasama, Shigeki Ito, Naoto Takahashi, Hideo Harigae
Call for papers - ESMO Real World Data and Digital Oncology
Artificial Intelligence in Clinical Oncology
Submission deadline: 15 January 2026
ESMO's Journal Portfolio
While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.
